N/A N=356 Parenting Young Children Study
Parenting · Parent-Child Relations · Opioid Misuse
Primary: Change From Baseline in Parenting Skills: Supporting Positive Behavior — 37.35; 37.43; 38.51; 37.49 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=110 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Neoplasms
Primary: Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks) — 0; 0; 0 Participants
Phase 1 N=16 KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory
Primary: Maximum Tolerated Dose (MTD) — 5; 5; 2 participants
N/A N=100 The Efficacy of Adjuvant Oral Care in Prevention of Ventilator Associated Pneumonia.
Pneumonia, Ventilator-Associated
Primary: Incidence of Ventilator-Associated Pneumonia (VAP) — 16; 27 Participants
N/A N=69 Reward Circuit Targeted iTBS
Transcranial Magnetic Stimulation
Primary: Change in Anhedonia Post-intervention and Washout — 6.4231; 5.4327 Scores on a scale — p=0.0452
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
N/A N=15 Combining Broad Based Light (BBL), Fractionated 1927 (MOXI) and Dual Wavelength 2940/1470 (HALO)
Pigment Skin
Primary: Change in Brown Spots at 1 Month From Baseline (Single Treatment Group) — 12.00; 5.00; 0.00; 5.00 count of spots
N/A N=197 Allofit® IT With HXPE in Total Hip Arthroplasty
Avascular Necrosis · Osteoarthritis, Hip · Inflammatory Arthritis
Primary: Survival of the Implant System — 89 participants
N/A N=30 Evaluation of Transcranial Photobiomodulation in Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Participant Improvement in ASD Symptoms as Assessed by the Clinical Global Impression of Improvement for Autism Spectrum Disorder (CGI-ASD-I) — 5; 5 Participants
N/A N=30 Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study
Non-Alcoholic Fatty Liver Disease · Non-Alcoholic Steatohepatitis
Primary: Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements of Hepatorenal Index (HRI) Ultrasound Biomarker for Liver Fat. — 1.7 Hepatorenal Index
N/A N=206 Just-in-time Adaptive Intervention Messaging in a Digital Weight Loss Intervention for Young Adults
Obesity · Overweight · Overweight and Obesity
Primary: Met Daily Weighing Goal — 4399; 4167; 1496; 1393 goals met — p=.03
N/A N=60 Effect of Super-Oxygenated Water on Blood Oxygen Saturation
Adult Subject
Primary: SpO2 Response Rate — 21; 11 Participants — p=0.010
Phase 3 N=10 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
Relapsing Multiple Sclerosis
Primary: Glial Activity Load on PET — 0.968; 0.799; 0.759 Z-score
N/A N=1,629 PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
Coronary Artery Disease
Primary: Percentage of Participants With Target Lesion Failure (TLF) and Constituent Elements — 5.4; 5.1; 0.3; 0.8 percentage of subjects with TLF
N/A N=34 Quantifying Energetic Demands of Walking for People With Cerebral Palsy
Cerebral Palsy
Primary: Net Nondimensional Oxygen Cost — -34.13; -15.86; 1.07; -0.60 Percent change relative to baseline